Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 8/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 8/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 9/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 9/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29998481 | 0.67 | CHRNB4 (0.61) | POLBCHRNB4CHRNA3AKR1C3CHRNB2 | |
| SCHEMBL27594106 | 0.64 | CHRNB4 (0.58) | POLBCHRNB4CHRNA3AKR1C3CHRNB2 | |
| SCHEMBL27057850 | 0.64 | CHRNB4 (0.58) | POLBCHRNB4CHRNA3AKR1C3CHRNB2 | |
| SCHEMBL29552004 | 0.64 | AKR1C3 (0.70) | POLBCHRNB4CHRNA3AKR1C3CHRNB2 | |
| SCHEMBL5198623 | 0.64 | AKR1C3 (0.70) | POLBCHRNB4CHRNA3AKR1C3CHRNB2 | |
| SCHEMBL7976910 | 0.63 | CA2 (0.47) | POLB | |
| SCHEMBL7186276 | 0.63 | CHRNB4 (0.56) | POLBCHRNB4CHRNA3AKR1C3CHRNB2 | |
| SCHEMBL29932734 | 0.63 | CHRNB4 (0.56) | POLBCHRNB4CHRNA3AKR1C3CHRNB2 | |
| SCHEMBL1982257 | 0.62 | CHRNB4 (0.54) | POLBCHRNB4CHRNA3AKR1C3CHRNB2 | |
| SCHEMBL28898321 | 0.62 | CHRNB4 (0.46) | POLBCHRNB4CHRNA3CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234419-A1 | SUBSTITUTED 3-AMINOISOXAZOLOPYRIDINES AS KCNQ2/3 MODULATORS | GRUNENTHAL GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234419-A1 | SUBSTITUTED 3-AMINOISOXAZOLOPYRIDINES AS KCNQ2/3 MODULATORS | KCNQ1, KCNQ2, KCNQ3 | POLB 4667/4885CHRNB4 422/4885CHRNA3 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.